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Introduction:
According to the
Malignant Hyperthermia
Association of the United
States (2015), “Malignant
hyperthermia (MH) is a
potentially fatal, inherited
disorder usually associated
with the administration of
certain general anesthetics
and/or the drug
succinylcholine.”
Malignant hyperthermia
has been presented to me
during hospital skills days
over the past year due to
the increased need for
knowledge regarding this
topic. I choose this topic
because I find it interesting
due to the fact that I could
encounter this in the
remainder of my days in
the intensive care unit, but
most importantly because
I will be dealing with these
drugs on a daily basis as a
Nurse Anesthetist.
Researching this topic in
detail and presenting it
will make me feel even
more comfortable if one of
my patients would
experience the negative
effects of anesthesia and
go into malignant
hyperthermia.

Signs and
Symptoms
As with all diseases and illness
there are signs and symptoms
that medical personnel should be
aware of and be able to recognize.
According to the Malignant
Hyperthermia Association of the
United States (2015), Signs and
symptoms for MH include:
•
Increased heart rate
•
Greatly increased body
metabolism
•
Muscle rigidity
•
Fever that may exceed 110
degrees F along with muscle
breakdown, derangements
of body chemicals and
increased acid content in the
blood.
More severe complications:
•
Cardiac arrest
•
Brain damage
•
Internal bleeding or failure
of other body systems
Malignant hyperthermia crisis can
mimic other complications and it
should be addressed quickly or
death could occur.

Underlying
Pathophysiology
Those who are susceptible to
malignant hyperthermia or experience
MH have a mutation which causes the
presence of abnormal proteins to build
up in the muscle cells of their body.
According the Kingler, Heiderich, Girard,
Gravino, Heffron, Johannsen, & Lehman
(2014), the mutation is found on the
ryanodine receptor type 1 (RyR1).”
Proteins that build up in the muscle cells
is a normal occurrence in the human
body, but these individuals when
exposed to certain anesthetic agents or
in some cases extreme heat or strenuous
exercise, it causes an abnormal release
of calcium from the sarcoplasmic
reticulum in the muscle cells. The
sarcoplasmic reticulum is where
calcium is storage and when this occurs
it results in a sustained muscle
contraction which increases metabolism
and heat production. Once the muscle
cells have been contracted for a period
of time they are eventually depleted of
adenosine triphosphate (ATP), which is
the source of cellular energy. The
muscle cells will not be able to survive
this and once they die the cells release
large amounts of potassium into the
bloodstream which causes
hyperkalemia. The hyperkalemia can
cause ventricular arrhythmias.
Myoglobin, muscle pigment, is also
released during this and can cause
injury to the kidneys. (Malignant
Hyperthermia Association, 2015).

Significance of Pathophysiology
Understanding the pathophysiology about MH can be beneficial for many
reasons. As stated by Herlich (2013), it is crucial for medical personnel to make a
more accurate diagnosis of perioperative fever or hyperthermia and subsequently
choose the proper course of treatment. This would increase patient outcomes,
decrease length of stays, etc. MH can have many poor outcomes if not treated
promptly and accurately. Release of potassium causes hyperkalemia which can
result in cardiac arrhythmias. Treating the high K will decrease the risk of cardiac
arrhythmias and or death. The release of myoglobin can be toxic to the kidneys, so
making sure to persevere kidney function with fluids would be beneficial. The
patient’s body temperature must be controlled so the brain does not become injured.
When comprehending what the body is going through during a MH crisis, those
caring for the patient are able to treat the underlying causes more effectively.
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Implications for Nursing Care
Nurses must be attentive and recognize when a patient is deteriorating. Patients
must be closely monitored for malignant hyperthermia as it can happen during
surgery and the first hour after anesthesia, which is the most crucial time. It also, can
occur if the anesthetic or succinylcholine is given in the emergency room or ICU for
intubation. Nurses must recognize hemodynamic changes, rising carbon dioxide
levels, increased temperature, muscle rigidity, and brownish colored urine. Once MH
is suspected the nurse should notify the physician and use all resources to help assist
with a patient whose body is going through an MH crisis. Orders will be given and a
protocol should be followed. Dantrolene must be reconstituted and pushed.
Tubes/drains should be flushed with chilled saline as well as chilled intravenous
fluids should be started. The patient should be moved to the intensive care unit and
monitored closely. The nurse caring for the patient should make sure the patient is
safe and cared for in an appropriate and timely manner.
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Conclusion
Malignant
hyperthermia can
occur in a wide
variety of areas and
those working in
areas where MH can
occur they must be
properly educated
and prepared to
recognize and act
properly so poor
patient outcomes
don’t occur. However,
according to Cain,
Riess, Gettrust, &
Novalija (2014) “Many
clinicians are
unprepared to
manage an MH crisis
in the perioperative
setting because it
requires the use of
low-frequency, highrisk skills and
procedures.
Simulation is a
recognized
educational method
for cumulative and
integrative learning in
a safe environment
that resembles reallife clinical scenarios”
(pg1). As clinicians we
must educate
ourselves and use all
our resources
including the MH
hotline who is ran by
the Malignant
Hyperthermia
Association of the
United States.

References
Cain, C. L., Riess, M. L., Gettrust,
L., & Novalija, J. (2014).
Malignant Hyperthermia
Crisis: Optimizing Patient
Outcomes Through
Simulation and
Interdisciplinary
Collaboration. AORN Journal,
99(2), 300-311.
doi:10.1016/j.aorn.2013.06.0
12
Herlich, A. (2013). Perioperative
temperature elevation: not all
hyperthermia is malignant
hyperthermia. Paediatric
Anaesthesia, 23(9), 842-850.
doi:10.1111/pan.12244
Klingler, W., Heiderich, S., Girard,
T., Gravino, E., Heffron, J. A.,
Johannsen, S., & ... LehmannHorn, F. (2014). Functional
and genetic characterization
of clinical malignant
hyperthermia crises: a multicentre study. Orphanet
Journal Of Rare Diseases,
9(1), 1-27.
doi:10.1186/1750-1172-9-8
What is MH? (2015). Retrieved
from Malignant Hyperthermia
Association of the United
States:
http://www.mhaus.org/

Additional Sources
Barnes, C., Stowell, K. M., Bulger, T.,
Langton, E., & Pollock, N. (2015).
Safe duration of postoperative
monitoring for malignant
hyperthermia patients
administered non-triggering
anesthesia: an update.
Anaesthesia & Intensive Care,
43(1), 98-104.
Brislin, R. P., & Theroux, M. C.
(2013). Core myopathies and
malignant hyperthermia
susceptibility: a review. Pediatric
Anaesthesia, 23(9), 834-841.
doi:10.1111/pan.12175
Heytens, L., Forget, P., Scholtès, J. L.,
& Veyckemans, F. (2015). The
changing face of malignant
hyperthermia: less fulminant,
more insidious. Anaesthesia &
Intensive Care, 43(4), 506-511.
Perry, S. M. (2014). CHAPTER 7:
Investigations on the
Relationship Between the
Autonomic Nervous System and
the Triggering of Malignant
Hyperthermia. Annual Review Of
Nursing Research, 32135-154.
doi:10.1891/0739-6686.32.135
Schneiderbanger, D., Johannsen, S.,
Roewer, N., & Schuster, F.
(2014). Management of
malignant hyperthermia:
diagnosis and treatment.
Therapeutics & Clinical Risk
Management, 10355-362.
doi:10.2147/TCRM.S47632
Seifert, P. C., Wahr, J. A., Pace, M.,
Cochrane, A. B., & Bagnola, A. J.
(2014). CRISIS
CONSIDERATIONS. Crisis
Management of Malignant
Hyperthermia in the OR. AORN
Journal, 100(2), 189-202.e1.
doi:10.1016/j.aorn.2014.06.014

